Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Open access

Abstract

Daratumumab (DARA) is a human CD38-specific IgG1 antibody that is in clinical development for the treatment of multiple myeloma (MM). The potential for IgG1 antibodies to induce macrophage-mediated phagocytosis, in combination with the known presence of macrophages in the tumor microenvironment in MM and other hematological tumors, led us to investigate the contribution of antibody-dependent, macrophage-mediated phagocytosis to DARA's mechanism of action. Live cell imaging revealed that DARA efficiently induced macrophage-mediated phagocytosis, in which individual macrophages rapidly and sequentially engulfed multiple tumor cells. DARA-dependent phagocytosis by mouse and human macrophages was also observed in an in vitro flow cytometry assay, using a range of MM and Burkitt's lymphoma cell lines. Phagocytosis contributed to DARA's anti-tumor activity in vivo, in both a subcutaneous and an intravenous leukemic xenograft mouse model. Finally, DARA was shown to induce macrophage-mediated phagocytosis of MM cells isolated from 11 of 12 MM patients that showed variable levels of CD38 expression. In summary, we demonstrate that phagocytosis is a fast, potent and clinically relevant mechanism of action that may contribute to the therapeutic activity of DARA in multiple myeloma and potentially other hematological tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19420862.2015.1007813

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Flow cytometry and live cell imaging reveals macrophage-mediated phagocytosis of CD38+ tumor cells in the presence of DARA. Co-cultures of mouse mφ and Daudi cells in the presence of 6.7 nM DARA or F(ab’)2 fragments thereof, E:T ratio of 1:1 (A, B) or 3:1 (C). (A) Double positive (DP) mφ were characterized as F4/80+calcein+CD19– and the percentage DP macrophages was calculated as described in Materials and Methods. (B) The percentage eliminated target cells was calculated from the number of remaining F4/80- cells as described in Materials & Methods. Each bar shows mean ± SEM, results from a representative experiment are shown (n = 3). (C) Time-lapse imaging microscopy, bright field images of a mouse mφ (arrow) that sequentially engulfed 5 individual Daudi cells (numbers) over a period of 800 s. The images are representative for observations in multiple independent phagocytosis experiments (n = 3) (****p < 0.0001 Bonferroni's multiple comparison test).
Figure 1. Flow cytometry and live cell imaging reveals macrophage-mediated phagocytosis of CD38+ tumor cells in the presence of DARA. Co-cultures of mouse mφ and Daudi cells in the presence of 6.7 nM DARA or F(ab’)2 fragments thereof, E:T ratio of 1:1 (A, B) or 3:1 (C). (A) Double positive (DP) mφ were characterized as F4/80+calcein+CD19– and the percentage DP macrophages was calculated as described in Materials and Methods. (B) The percentage eliminated target cells was calculated from the number of remaining F4/80- cells as described in Materials & Methods. Each bar shows mean ± SEM, results from a representative experiment are shown (n = 3). (C) Time-lapse imaging microscopy, bright field images of a mouse mφ (arrow) that sequentially engulfed 5 individual Daudi cells (numbers) over a period of 800 s. The images are representative for observations in multiple independent phagocytosis experiments (n = 3) (****p < 0.0001 Bonferroni's multiple comparison test).CC BY · PubMed Central
Figure 2. Induction of macrophage-mediated phagocytosis is strongly impaired for an IgG2 isotype variant of DARA. Phagocytosis of Daudi cells by mouse mφ in the presence of 6.7 nM mAb, E:T ratio of 1:1. (A) Double-positive (DP) mφ were characterized as F4/80+calcein+CD19– and the percentage DP macrophages was calculated as described in Materials and Methods. (B) Percentage eliminated target cells was calculated using the number of remaining F4/80- cells as described in Materials & Methods. Each bar shows mean ± SEM, results from a representative experiment (n = 3) (**p < 0.01, ****p < 0.0001 Bonferroni's multiple comparison test).
Figure 2. Induction of macrophage-mediated phagocytosis is strongly impaired for an IgG2 isotype variant of DARA. Phagocytosis of Daudi cells by mouse mφ in the presence of 6.7 nM mAb, E:T ratio of 1:1. (A) Double-positive (DP) mφ were characterized as F4/80+calcein+CD19– and the percentage DP macrophages was calculated as described in Materials and Methods. (B) Percentage eliminated target cells was calculated using the number of remaining F4/80- cells as described in Materials & Methods. Each bar shows mean ± SEM, results from a representative experiment (n = 3) (**p < 0.01, ****p < 0.0001 Bonferroni's multiple comparison test).CC BY · PubMed Central
Figure 3. Phagocytosis contributes to the in vivo anti-tumor effect of DARA. (A) Kaplan-Meier plot showing time to tumor progression (cutoff set at a tumor volume > 800 mm3) for mice that had been inoculated s.c. with 20 × 106 Daudi-luc cells (8 mice per group). Subsequently, mice were treated i.p. with 250 μg mAb per mouse (∼12.5 mg/kg) at day 0. Tumor progression was significantly reduced in DARA-K322A-treated mice compared to DARA-IgG2-K322A treatment (p < 0.004 Mantle-Cox log-rank test at time to progression). (B) Kaplan-Meier plot showing time to tumor progression (cutoff set at bioluminescence > 50 000 cpm) for mice that had been inoculated i.v. with 2.5×106 Daudi-luc cells (10 mice per group). Subsequently, mice were treated i.p. with 10 μg mAb per mouse (∼0.5 mg/kg) at day 0. Tumor progression was significantly reduced in DARA-K322A-treated vs. DARA-IgG2-K322A-treated mice (p < 0.001 Mantle-Cox log-rank test at time to progression).
Figure 3. Phagocytosis contributes to the in vivo anti-tumor effect of DARA. (A) Kaplan-Meier plot showing time to tumor progression (cutoff set at a tumor volume > 800 mm3) for mice that had been inoculated s.c. with 20 × 106 Daudi-luc cells (8 mice per group). Subsequently, mice were treated i.p. with 250 μg mAb per mouse (∼12.5 mg/kg) at day 0. Tumor progression was significantly reduced in DARA-K322A-treated mice compared to DARA-IgG2-K322A treatment (p < 0.004 Mantle-Cox log-rank test at time to progression). (B) Kaplan-Meier plot showing time to tumor progression (cutoff set at bioluminescence > 50 000 cpm) for mice that had been inoculated i.v. with 2.5×106 Daudi-luc cells (10 mice per group). Subsequently, mice were treated i.p. with 10 μg mAb per mouse (∼0.5 mg/kg) at day 0. Tumor progression was significantly reduced in DARA-K322A-treated vs. DARA-IgG2-K322A-treated mice (p < 0.001 Mantle-Cox log-rank test at time to progression).CC BY · PubMed Central
Figure 4. Human macrophages induce DARA-dependent phagocytosis of BL and MM cell lines. Phagocytosis of BL cells (left panel) or MM cells (right panel) by human mφ in the presence of 6.7 nM mAb, E:T ratio of 2:1. (A) Percentage of double positive (DP) mφ characterized as CD11b+calcein+target Ag–. (B) Percentage of eliminated target cells calculated from the number of remaining CD11b- cells as described in Materials & Methods. Each bar shows mean ± SEM, results from a representative experiment (n = 3) (**p < 0.01, ***p < 0.001, ****p < 0.0001 Bonferroni's multiple comparison test).
Figure 4. Human macrophages induce DARA-dependent phagocytosis of BL and MM cell lines. Phagocytosis of BL cells (left panel) or MM cells (right panel) by human mφ in the presence of 6.7 nM mAb, E:T ratio of 2:1. (A) Percentage of double positive (DP) mφ characterized as CD11b+calcein+target Ag–. (B) Percentage of eliminated target cells calculated from the number of remaining CD11b- cells as described in Materials & Methods. Each bar shows mean ± SEM, results from a representative experiment (n = 3) (**p < 0.01, ***p < 0.001, ****p < 0.0001 Bonferroni's multiple comparison test).CC BY · PubMed Central
Figure 5. DARA-dependent phagocytosis of patient MM cells by human macrophages. Patient MM cells were incubated with human mφ, obtained from healthy donors (E:T ratio 2:1), in the presence of 6.7 nM mAb. To correct for differences in potency between batches of human donor mφ obtained from different donors, results were normalized by calculating the ratio of patient MM cells to an internal Daudi cell standard (observed in the same experiment). The 12 patient samples are ranked according to their CD38 expression level, with cells from patient 6 exhibiting lowest (10,000 molecules per cells) and patient 5 highest (550,000 molecules/cell) CD38 expression. (A) Normalized percentage of DARA-specific double positive (DP) mφ. (B) Normalized percentage of DARA-specific eliminated target cells. Each bar shows mean ± SEM of triplicates.
Figure 5. DARA-dependent phagocytosis of patient MM cells by human macrophages. Patient MM cells were incubated with human mφ, obtained from healthy donors (E:T ratio 2:1), in the presence of 6.7 nM mAb. To correct for differences in potency between batches of human donor mφ obtained from different donors, results were normalized by calculating the ratio of patient MM cells to an internal Daudi cell standard (observed in the same experiment). The 12 patient samples are ranked according to their CD38 expression level, with cells from patient 6 exhibiting lowest (10,000 molecules per cells) and patient 5 highest (550,000 molecules/cell) CD38 expression. (A) Normalized percentage of DARA-specific double positive (DP) mφ. (B) Normalized percentage of DARA-specific eliminated target cells. Each bar shows mean ± SEM of triplicates.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 4

  1. Munn DH, 1991, Cancer Res, 51, 1117
  2. 10.1309/74r4tb90buwh27jx · doi:10.1309/74r4tb90buwh27jx · Paper page
  3. Gimsing P, 2011, ASH Annu Meeting Abstr, 118, 1873
  4. Plesner T, 2012, ASH Annu Meeting Abstr, 120, 73

Cited by

See all 534

Metadata

Authors
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., & Parren, P. W.
Affiliations
  • Genmab (United States) (US)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • University Medical Center Utrecht (NL)
  • University of Southern Denmark (DK)
Corresponding author
Parren, Paul WHI
Venue
mAbs
Published
2015-03-04
Volume
7
Issue
2
Pages
311-320
ISSN
  • 1942-0862 (ISSN-L)
  • 1942-0870
OpenAlex
W1585625390
Cited by
521
References
48
Citations by year
2026: 28 · 2025: 32 · 2024: 38 · 2023: 49 · 2022: 50 · 2021: 65 · 2020: 76 · 2019: 51 · 2018: 43 · 2017: 42 · 2016: 36 · 2015: 8
FWCI
33.75
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • mAbs (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
Keywords
daratumumab, antibody-mediated phagocytosis, macrophage phagocytosis, CD38, multiple myeloma, Burkitt lymphoma, tumor microenvironment, anticancer activity, CD38 expression
MeSH terms
Animals, Antibodies, Monoclonal, Antibodies, Neoplasm, Humans, Lymphoma, Macrophages, Multiple Myeloma, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Cytophagocytosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. https://app.cochat.ai/papers/10.1080/19420862.2015.1007813
The paper
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., & Parren, P. W. (2015). Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs. https://doi.org/10.1080/19420862.2015.1007813

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.